Barter P J, Gorjatschko L, Hopkins G J
Biochim Biophys Acta. 1982 Mar 12;710(3):349-58. doi: 10.1016/0005-2760(82)90118-7.
Different methods of incorporating esterified [3H]cholesterol into human high density lipoproteins (HDL) have been assessed in terms of their influence on the subsequent rate at which esterified [3H]cholesterol was transferred from HDL to other plasma lipoproteins in 37 degrees C incubations containing tracer amounts of the labelled preparations added to aliquots of a common pool of unlabelled human plasma. Two basic methods were used to label the HDL esterified cholesterol: (a) by the action of lecithin: cholesterol acyltransferase in incubations of plasma containing exogenous [3H]cholesterol and (b) by exchange in incubations of plasma containing preparations of prelabelled LDL. The exchange labelling approach was also used to examine the effects of various HDL compositional changes on the subsequent behaviour of its esterified [3H]cholesterol. It was found that the source of the label, per se, whether from the esterification of exogenous [3H]cholesterol or from exchange with labeled LDL, had no influence on the subsequent behaviour of HDL esterified [3H]cholesterol. However, modification of the HDL composition during the labelling process had profound effects. For example, in preparations in which the esterified cholesterol content of the labelled HDL was increased by the action of lecithin: cholesterol acyltransferase, there was a reduced rate of transfer of esterified [3H]cholesterol out of the HDL fraction in subsequent incubations of the labelled HDL with fresh, unlabelled plasma. Conversely, when the esterified cholesterol content of the labelled HDL had been decreased by pre-incubation with Intralipid or very low density lipoproteins (VLDL), the subsequent rate of transfer of esterified [3H]cholesterol out of the HDL fraction was increased markedly. It has been concluded that to obtain a biologically valid, labelled tracer of human HDL esterified cholesterol, the labelling should be achieved with minimal modification to the HDL composition. This means labelling by exchange in incubations in which lecithin: cholesterol acyltransferase is inhibited in plasma from which VLDL has been removed.
在含有微量标记制剂的未标记人血浆等分试样于37℃孵育的条件下,评估了将酯化的[3H]胆固醇掺入人高密度脂蛋白(HDL)的不同方法对随后酯化的[3H]胆固醇从HDL转移至其他血浆脂蛋白的速率的影响。使用了两种基本方法标记HDL酯化胆固醇:(a)在含有外源性[3H]胆固醇的血浆孵育中通过卵磷脂:胆固醇酰基转移酶的作用;(b)在含有预先标记的低密度脂蛋白(LDL)制剂的血浆孵育中通过交换。交换标记方法也用于检查各种HDL组成变化对其酯化的[3H]胆固醇随后行为的影响。发现标记的来源本身,无论是来自外源性[3H]胆固醇的酯化还是来自与标记的LDL的交换,对HDL酯化的[3H]胆固醇的随后行为均无影响。然而,在标记过程中HDL组成的改变具有深远影响。例如,在通过卵磷脂:胆固醇酰基转移酶的作用使标记的HDL的酯化胆固醇含量增加的制剂中,在随后将标记的HDL与新鲜的未标记血浆孵育时,酯化的[3H]胆固醇从HDL组分中转移出的速率降低。相反,当通过与英脱利匹特或极低密度脂蛋白(VLDL)预孵育使标记的HDL的酯化胆固醇含量降低时,酯化的[3H]胆固醇从HDL组分中随后的转移速率显著增加。得出的结论是,为了获得生物学上有效的人HDL酯化胆固醇标记示踪剂,标记应在对HDL组成进行最小改变的情况下实现。这意味着在去除了VLDL的血浆中进行孵育交换标记,其中卵磷脂:胆固醇酰基转移酶被抑制。